Literature DB >> 22038552

Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy.

Katsunori Iijima1, Nobuyuki Ara, Yasuhiko Abe, Tomoyuki Koike, Wataru Iwai, Toshimitsu Iwabuchi, Takafumi Ichikawa, Yayoi Kamata, Kazuhiko Ishihara, Tooru Shimosegawa.   

Abstract

BACKGROUND: Low-dose aspirin is known to cause upper gastrointestinal complications. The mechanism by which the aspirin disrupts gastric mucosal integrity remains to be clarified. In this study we investigated the temporal association of gastric secretory parameters (acid and mucus) with aspirin-induced gastropathy.
METHODS: In 42 long-term low-dose aspirin-takers and the same number of sex- and age-matched controls, pentagastrin-stimulated gastric juice was collected for 10 min during endoscopic examination. The collected gastric juice was divided and half was submitted to analysis for gastric acid (mEq/10 min) and the other half was analyzed for mucin (mg hexose/10 min) output. The grade of gastric mucosal injury was assessed endoscopically according to the modified Lanza score, and a score of more than 4 was defined as the presence of severe gastropathy.
RESULTS: While gastric acid secretion did not differ significantly between aspirin-takers and controls, gastric mucus secretion, in terms of mucin output, was significantly increased in aspirin-takers compared to controls (4.1 (SD 4.8) vs. 2.3 (1.4) mg hexose/10 min, P < 0.05). Consequently, the acid/mucin ratio was significantly decreased in aspirin-takers compared to controls (1.2 (1.0) vs. 1.7 (1.4), P < 0.05). In the subanalysis of 25 aspirin-takers without severe gastropathy, gastric mucus secretion was increased and the acid/mucus ratio was decreased compared with controls, but there was no such association in the remaining 17 aspirin-takers with severe gastropathy.
CONCLUSION: Overall, gastric mucus secretion is increased in aspirin-takers, suggesting a functional adaptive response to long-term administration of the drug. However, it is possible that the adaptive response is impaired in some aspirin takers, who might be susceptible to severe upper gastrointestinal complication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038552     DOI: 10.1007/s00535-011-0478-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  5 in total

1.  Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects.

Authors:  K Iijima; T Koike; N Ara; K Nakagawa; Y Kondo; K Uno; W Hatta; N Asano; A Imatani; T Shimosegawa
Journal:  J Gastroenterol       Date:  2014-06-22       Impact factor: 7.527

2.  Ulcerogenic and intestinal motility/transit stimulating actions of nevirapine in albino Wistar rats.

Authors:  Elizabeth Bassey Umoren; Agona Odeh Obembe; Eme Effiom Osim
Journal:  J Physiol Biochem       Date:  2013-03-28       Impact factor: 4.158

3.  Reactive increase in gastric mucus secretion is an adaptive defense mechanism against low-dose aspirin-induced gastropathy.

Authors:  K Iijima; T Iwabuchi; N Ara; T Koike; H Shinkai; Y Kamata; T Ichikawa; K Ishihara; T Shimosegawa
Journal:  Dig Dis Sci       Date:  2013-05-07       Impact factor: 3.199

4.  Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.

Authors:  Anna E Prizment; Christopher Staley; Guillaume C Onyeaghala; Sithara Vivek; Bharat Thyagarajan; Robert J Straka; Ryan T Demmer; Dan Knights; Katie A Meyer; Aasma Shaukat; Michael J Sadowsky; Timothy R Church
Journal:  Aliment Pharmacol Ther       Date:  2020-08-08       Impact factor: 8.171

5.  Does Helicobacter pylori Exacerbate Gastric Mucosal Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? A Multicenter, Retrospective, Case-Control Study.

Authors:  Yoshiyasu Kono; Hiroyuki Okada; Ryuta Takenaka; Ko Miura; Hiromitsu Kanzaki; Keisuke Hori; Masahide Kita; Takao Tsuzuki; Seiji Kawano; Yoshiro Kawahara; Kazuhide Yamamoto
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.